Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:PKI

Revvity (PKI) Stock Price, News & Analysis

Revvity logo

About Revvity Stock (NYSE:PKI)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$115.24
$137.11
52-Week Range
N/A
Volume
1.63 million shs
Average Volume
851,117 shs
Market Capitalization
$14.57 billion
P/E Ratio
15.01
Dividend Yield
0.24%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Revvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revvity and its competitors with MarketBeat's FREE daily newsletter.

PKI Stock News Headlines

Revvity, Inc. (RVTY)
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Revvity Inc PKI
See More Headlines

PKI Stock Analysis - Frequently Asked Questions

Revvity, Inc. (NYSE:PKI) issued its quarterly earnings data on Thursday, May, 11th. The medical research company reported $1.01 earnings per share for the quarter, missing analysts' consensus estimates of $1.07 by $0.06. The medical research company had revenue of $674.87 million for the quarter, compared to analyst estimates of $686.30 million. Revvity had a net margin of 28.94% and a trailing twelve-month return on equity of 11.17%.

Revvity's board approved a stock buyback plan on Thursday, May 11th 2023, which allows the company to buy back $600,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 4.1% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's management believes its stock is undervalued.

Revvity subsidiaries include BioLegend, Immunodiagnostic Systems, Nexcelom Bioscience, SIRION Biotech, Oxford Immunotec, Horizon Discovery, Cisbio.com, and others.

Based on aggregate information from My MarketBeat watchlists, some other companies that Revvity investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Visa (V), Home Depot (HD) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/11/2023
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:PKI
Employees
16,700
Year Founded
1937

Profitability

Trailing P/E Ratio
15.01
Forward P/E Ratio
N/A
P/E Growth
0.5
Net Income
$569.18 million
Pretax Margin
13.81%

Debt

Sales & Book Value

Annual Sales
$3.31 billion
Price / Cash Flow
9.88
Book Value
$58.49 per share
Price / Book
N/A

Miscellaneous

Free Float
125,755,000
Market Cap
$14.57 billion
Optionable
Optionable
Beta
1.10

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NYSE:PKI) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners